Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUIDEL ACQUIRES MARKETING RIGHTS TO SAFEPLAN OTC FERTILITY TEST

This article was originally published in The Tan Sheet

Executive Summary

QUIDEL ACQUIRES MARKETING RIGHTS TO SAFEPLAN OTC FERTILITY TEST from Dutch pharmaceutical firm Akzo in a deal announced Jan. 4. Under terms of the agreement, Akzo will transfer worldwide marketing fights to Quidel in exchange for an undisclosed transfer fee and royalty payments on net product sales. Quidel will also provide Akzo with the option to co-market the product in exchange for an undisclosed sum upon FDA marketing clearance of SafePlan and upon initial sales of the product in the U.S.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel